On October 28, 2019 Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, reported their participation at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) occurring November 6th-10th in National Harbor, Maryland (Press release, Applied BioMath, OCT 28, 2019, View Source [SID1234549946]). They will present two posters at the conference Friday, November 8th.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Katie Williams, PhD, Associate Director, Business Development, Applied BioMath will present the poster titled "A semi-mechanistic platform model to capture individual animal responses to checkpoint inhibitors in a syngeneic mouse model." In this work, we describe the generation of a model platform that captures essential aspects of the pharmacokinetics, cellular and tumor growth effects of murine surrogates of two checkpoint therapeutic antibodies, anti-PD1 and anti-CTLA4, in the CT26 syngeneic tumor model. The model describes individual animal responses regarding drug exposure, key intra-tumoral cell kinetics and tumor volume changes and provides biologically plausible explanations for the observed differences between good and poor responders to treatment with anti-PD1 or anti-CTLA4.
Jennifer Park, PhD, Director, Business Development, Applied BioMath will present the poster titled "Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients." In this work, a semi-mechanistic pharmacokinetic/target-occupancy (PKTO) model was developed with in vitro, preclinical and clinical data to facilitate dose selection of CK-301 (also known as TG-1501, cosibelimab), an anti-PD-L1 monoclonal antibody (mAb), for ongoing and future clinical trials in oncology patients. The model was used to compare the PK and tumor target occupancy (TO) at steady state under various dosing regimens with cosibelimab to those with three marketed anti-PD-L1 mAbs (i.e. atezolizumab, durvalumab and avelumab).
"We are excited to participate at SITC (Free SITC Whitepaper) for the first time this year!" said John Burke, PhD, Co-founder, President and CEO, Applied BioMath. "We hope to introduce the benefits of systems modeling and simulation to SITC (Free SITC Whitepaper) attendees, and how this analysis can be applied to cancer immunotherapy research and development from very early development through clinical trials."
For more information about all of Applied BioMath’s events, visit View Source